Findings demonstrate that targeting TGF-β alleviates renal injury in hypertensive models, suggesting a new treatment approach.
A number of studies have identified transforming growth factor-β (TGF-β) as a critical factor in renal diseases such as glomerulosclerosis and mesangioproliferative glomerulonephritis. TGF-β stimulates proliferation of mesangial cells, production of extracellular matrix components and induces epithelial-mesenchymal transformation in renal tissue, which plays a critical role in the pathogenesis of renal injury. Thus, TGF-β is a treatment target in renal diseases. However, pro gressive renal diseases cannot be cured with present medical technologies. We have developed ribozymes and a novel gene silencer pyrrole-imidazole polyamide targeted to TGF-β that effectively ameliorate renal in jury in hypertensive rats.
No takes yet. Share an insight, caveat, or question.
Fukuda et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: